BACKGROUND: ETC-1002 is an oral, once-daily, first-in-class medication being developed to treat hypercholesterolemia.
Statins are the cornerstone of prevention and treatment of cardiovascular disease but can produce statin-associated muscle symptoms in 5% to 29% of patients. [1] [2] [3] [4] There is no universally accepted definition for statin intolerance. The National Lipid Association Statin Intolerance Panel defines it as a patient's inability to tolerate $2 statins, at least 1 at the lowest approved daily dose and another at any daily dose. 1 Muscle symptoms including pain, stiffness, cramping, or weakness, usually without serum creatine kinase (CK) elevations, are the primary manifestations of statin intolerance. 1, 4, 5 Statin-associated muscle symptoms are an important clinical problem because statin discontinuation in hypercholesterolemic patients increases cardiovascular risk. 4 Patients who discontinue statin treatment because of intolerance show a trend toward decreased 8-year survival compared with patients who continue statin therapy (log-rank P value, .08). 5 The challenge of muscle-related statin intolerance and the need for research into therapies for this population are recognized in the latest American College of Cardiology/American Heart Association cholesterol management guidelines, 6 the National Lipid Association's Statin Safety Task Force recommendations, 1 and the European Atherosclerosis Society Consensus Panel statement on statin-associated muscle symptoms. 4 ETC-1002 is a first-in-class, once-daily, oral agent that lowers low-density lipoprotein cholesterol (LDL-C) by direct inhibition of hepatic adenosine triphosphate citrate lyase, leading to reduced de novo cholesterol synthesis and increased LDL-receptor expression. [7] [8] [9] ETC-1002 in doses from 120 mg to 240 mg daily reduced LDL-C by 27% to 43% in phase 2a clinical trials of various hypercholesterolemic patient populations, including patients with type 2 diabetes mellitus and patients with muscle-related statin intolerance. [10] [11] [12] The present phase 2b study (NCT01941836) compared the efficacy and safety of ETC-1002 monotherapy (120 mg or 180 mg daily) and ETC-1002 combined with ezetimibe 10 mg (EZE) vs EZE monotherapy among hypercholesterolemic patients with or without a history of statin-related muscle symptoms.
Methods

Study objectives
The primary objective was to assess the LDL-Clowering effect of ETC-1002 monotherapy (120 mg or 180 mg daily) vs EZE monotherapy in hypercholesterolemic patients with or without statin intolerance. Secondary objectives were to characterize the dose response of ETC-1002, evaluate the impact of treatment on other lipid and cardiometabolic biomarkers, compare the LDL-Clowering effect of ETC-1002 plus EZE combination therapy with EZE monotherapy, and characterize the safety and tolerability of the treatment regimens, including muscle-related adverse events (AEs).
Study population
Medically stable, hypercholesterolemic men and women aged 18 through 80 years with a body mass index between 18 and 45 kg/m 2 were included in the study. Eligible patients had fasting, calculated LDL-C values between 130 and 220 mg/dL and a fasting triglyceride level #400 mg/dL after washout of lipid-regulating drugs. The study population included both statin-tolerant and statinintolerant participants. Statin intolerance was defined as the inability to tolerate $2 statins because of musclerelated symptoms such as pain, weakness, or cramping that began or increased during statin therapy and resolved on statin discontinuation. At least 1 statin must have been administered at the lowest approved daily dose, defined as rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg, lovastatin 20 mg, pravastatin 40 mg, fluvastatin 40 mg, or pitavastatin 2 mg. Treatment with less than the lowest approved daily dose of a statin (ie, skipping days) was considered equivalent to not tolerating 1 statin at the lowest approved daily dose. Patients were excluded if they had clinically significant cardiovascular disease (including acute coronary syndromes, stroke, transient ischemic attack, carotid or peripheral artery disease, decompensated heart failure, uncontrolled hypertension, or cardiac arrhythmias); type 1 diabetes mellitus; uncontrolled type 2 diabetes mellitus; non-statin-related musculoskeletal complaints; uncorrected hypothyroidism; liver or renal dysfunction; unexplained CK elevations off statin treatment .3 times the upper limit of normal; ingested ,80% of drug during single-blind run-in; or used anticoagulants, systemic corticosteroids, cyclosporine, metformin, or thiazolidinediones within 3 months of screening.
Overall study design and plan
This phase 2b, randomized, double-blind, active comparator-controlled, parallel-group study was conducted at 70 sites in the United States from September 16, 2013, to August 7, 2014 , and consisted of a 6-week screening phase (week 26 to week 0) and a 12-week double-blind treatment period (week 0 to week 12). Patients underwent a 5-week washout of all lipid-regulating drugs and dietary supplements and abstained from these drugs and supplements throughout the study. Patients also underwent a 5-week, single-blind placebo run-in during the screening period (week 25 to week 0). This single-blind placebo run-in period was used to eliminate patients with muscle-related AEs during placebo treatment. Patients reporting new or worsening unexplained muscle-related AEs during this runin period were excluded from the study.
Patients were stratified Individual institutional review boards approved the clinical study protocol and informed consent documents. Written informed consent was obtained from all participants before any study-related procedures.
Efficacy endpoints
The primary endpoint was the percent change from baseline to week 12 in calculated LDL-C in patients treated with ETC-1002 monotherapy vs those treated with EZE alone. Secondary endpoints included the dose-response relationship between ETC-1002 and the percent change in LDL-C from baseline to week 12, the percent change in LDL-C from baseline to week 12 in patients treated with ETC-1002 plus EZE vs those treated with EZE alone, and the percent change from baseline to week 12 for all treatment groups in LDL particle number, apolipoprotein B, total cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, HDL particle number, apolipoprotein A-I, triglycerides, very low-density lipoprotein (VLDL) particle number, and high-sensitivity C-reactive protein (CRP). Lipoprotein particle number was measured using nuclear magnetic resonance imaging.
Safety endpoints
The safety of ETC-1002 was assessed using treatmentemergent AEs; hematology, serum chemistry, and urinalysis laboratory values; physical examination findings; vital sign measurements; electrocardiogram readings; weight; and ankle and waist circumference measurements. AEs were coded using the Medical Dictionary for Regulatory Activities, version 16.0, and evaluated by the investigator for severity and relation to study drug. Muscle-related AEs were defined as those from the system organ class of musculoskeletal and connective tissue disorders, except for those that were not obviously muscle related. Terms included in the muscle-related AE analysis were selected from this system organ class after database lock and before unblinding.
Statistical plan and analyses
The study was designed to include 322 patients: 92 patients in each monotherapy group and 23 patients in each combination therapy group. Sample size calculations were performed using nQuery Advisor, version 7.0 (Statistical Solutions, Cork, Ireland). The sample size of 92 patients per monotherapy group was expected to provide 90% power to detect a difference of 10% in the absolute percent change from baseline to week 12 in LDL-C between either ETC-1002 treatment groups and the EZE monotherapy group. This calculation was based on a 2-sided t test at the 5% level of significance and assumed a common standard deviation of 15% in the statin-tolerant patients and 22% in the statin-intolerant patients with a dropout rate of 15%.
Efficacy analyses were performed on the modified intent-to-treat population, which consisted of randomized patients who had a baseline assessment, received at least 1 dose of study medication, and had at least 1 on-treatment assessment, excluding assessments taken .2 days after a dose of study drug. Safety analyses were performed on the safety population, which included randomized patients who received at least 1 dose of study drug. Baseline patient characteristics were summarized for the safety population by treatment group and statin-tolerance subgroup.
An analysis of covariance was used to compare each ETC-1002 treatment group with EZE monotherapy for each of the efficacy endpoints. The primary model included the effects of treatment and statin intolerance and the baseline value as a covariate. Baseline was defined as the mean of values from weeks 21 and 0 for LDL-C, non-HDL-C, total cholesterol, HDL-C, and triglycerides. For all other lipid and biomarker measures, baseline was defined as the last value before the first dose of study drug. Missing values at week 12 were imputed using the last-observation carriedforward procedure. When LDL-C could not be calculated (ie, triglycerides .400 mg/dL), beta-quantification measurements were used to determine LDL-C values. Least-square (LS) means and standard errors were obtained for each treatment group; differences in LS means and P values were obtained for the treatment comparisons. Graphical methods (eg, normal probability plot and histogram of residuals, plot of residuals vs predicted values) or analytical methods (eg, Shapiro-Wilk test), or both, were used to assess the model assumptions. Because of departures from normality observed in the parameters of triglycerides, CRP, and VLDL particle number, nonparametric analyses were performed for these measures, with P values obtained from the Wilcoxon rank-sum test and median values presented.
Actual values, changes from baseline, and percent changes from baseline in calculated LDL-C and secondary lipid and biomarker measures were summarized using descriptive statistics by treatment group and time point. Percent changes from baseline in LDL-C also were summarized by statin-tolerance subgroup. To assess the doseresponse relationship for ETC-1002 monotherapy, the primary analysis of covariance model was used for the comparison of ETC-1002 120 mg and ETC-1002 180 mg. Statistical testing of the efficacy endpoints was 2-sided and conducted at the 5% level of significance with no adjustment for multiple comparisons.
For the evaluation of safety, the incidence of AEs was summarized by system organ class and preferred term for each treatment group. Muscle-related AEs also were summarized by statin-tolerance subgroup. Actual values and changes from baseline in clinical laboratory parameters, vital sign measurements, electrocardiogram tracings, body weight, and ankle and waist circumference measurements were summarized using descriptive statistics by treatment group and time point.
Results
Patient disposition and baseline characteristics
Of 690 patients screened, 341 were excluded, mainly for failure to satisfy inclusion criteria (Fig. 1) . Of the 349 randomized patients (177 statin intolerant and 172 statin tolerant), 309 patients completed the study. The 40 who discontinued participation did so most commonly because of AEs. A higher percentage of statin-tolerant patients (93%) than statin-intolerant patients (84%) completed the study. The safety population included 348 patients as 1 statin-tolerant patient discontinued before receiving any study drug.
Most patients were non-Hispanic Caucasians with similar numbers of men and women (Table 1) . Mean age, baseline lipid values, and National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III risk category were slightly higher in statin-intolerant patients. The most common prestudy statin-associated muscle complaints were bilateral calf and thigh pain (data not shown). Most statin-intolerant patients historically experienced the onset of statin-associated muscle symptoms within 1 to 2 weeks of statin initiation and most had resolution of symptoms within 1 to 2 weeks of discontinuation.
Efficacy endpoints ETC-1002 alone or in combination with EZE reduced LDL-C from baseline to week 12 more than EZE monotherapy (Table 2) . LDL-C reductions were greatest with the combination of ETC-1002 120 mg (43%) or 180 mg (48%) plus EZE (P , .0001 vs EZE alone, both comparisons). The combination treatment effect of ETC-1002 plus EZE was approximately equal to the sum of their individual effects on LDL-C. The LDL-C reduction was slightly, but not significantly, higher with ETC-1002 180 mg alone (30%) than with 120 mg alone (27%) (P 5 .15). The percent reductions in LDL-C with ETC-1002 were similar in statin-intolerant and statin-tolerant patients (Fig. 2) . LDL-C reductions were apparent and steady after 2 weeks of treatment (Fig. 3) .
ETC-1002 alone or with EZE reduced LDL particle number, apolipoprotein B, total cholesterol, and non-HDL-C more than EZE alone (Table 2) . Median values for CRP decreased from baseline to the week 12 endpoint by 30% with ETC-1002 120 mg and 40% with ETC-1002 180 mg. These CRP reductions in the ETC-1002 monotherapy groups were significantly greater (P , .01, both comparisons) than the 10% reduction observed with EZE alone (Table 2 ). ETC-1002 had minimal effect on triglycerides and VLDL particle number (Table 2) . HDL-C decreased with ETC-1002 treatment (by 3% to 6%) and increased with EZE alone (by 5%; P , .0001 to P , .05 for ETC-1002 groups vs EZE alone; Table 2 ). ETC-1002 did not alter HDL particle number or apolipoprotein A-I vs EZE alone, although apolipoprotein A-I did decrease Figure 1 Disposition of patients. *One patient who was statin tolerant was randomized but discontinued before receiving study drug. EZE, ezetimibe; mITT, modified intent-to-treat; Pop., population. more with ETC-1002 180 mg plus EZE than with EZE alone.
Safety endpoints
The incidence of AEs in each ETC-1002 monotherapy group was similar to EZE alone (Table 3) . Most AEs were mild or moderate in severity. AEs deemed possibly, probably, or definitely related to study drug were least common with ETC-1002 120 mg and most frequent with ETC-1002 180 mg plus EZE. The frequency of AEs resulting in study discontinuation was similar between the ETC-1002 treatment groups and EZE. More statin-intolerant patients (n 5 17) experienced AEs resulting in discontinuation than did statin-tolerant patients (n 5 3). Four serious AEs were reported (Table 3) , 3 of which were unrelated to study drug and did not result in discontinuation (hemothorax with ETC-1002 120 mg, pancreatitis relapse with ETC-1002 180 mg, and transient ischemic attack with EZE). One sudden death of unknown cause in a patient taking ETC-1002 120 mg was deemed possibly related to study drug as a temporal relationship could not be excluded.
Muscle AEs were less frequent and caused fewer discontinuations with ETC-1002 monotherapy than with EZE. In the entire study population, myalgia was the most common muscle-related AE, occurring in 3% of patients treated with ETC-1002 120 mg, 1% with ETC-1002 180 mg, 6% with EZE alone, 8% with ETC-1002 120 mg plus EZE, and 4% with ETC-1002 180 mg plus EZE. Muscle-related AEs were more common among statinintolerant than statin-tolerant patients ( Table 4) . The most common muscle-related AE in statin-intolerant patients was myalgia, which was least frequent in the ETC-1002 monotherapy groups.
Overall, no clinically meaningful, dose-related trends in laboratory changes or abnormalities were observed. There also were no clinically meaningful changes in physical examination findings, vital sign measurements, electrocardiogram readings, weight, or waist or ankle circumference measurements. Alanine aminotransferase or aspartate aminotransferase, or both, increased .3 times the upper limit of normal at any measurement in 1 patient treated with ETC-1002 120 mg, 2 patients with ETC-1002 180 mg, 1 patient with EZE, and 1 patient with ETC-1002 120 mg Figure 2 Percent changes from baseline in LDL-C, stratified by statin tolerance. Week 12 or last observation carried forward is the endof-study endpoint and differs slightly from week 12 value; P values vs EZE monotherapy were determined by an analysis of covariance model with terms for treatment and statin intolerance and baseline value as a covariate. *P # .05 vs EZE; † P # .01 vs EZE; ‡ P , .0001 vs EZE. EZE, ezetimibe; LS, least square. Error bars represent standard error. Figure 3 Percent changes from baseline in LDL-C by treatment group and time. P values vs EZE at week 12 endpoint are shown. Week 12 or last observation carried forward is the end-of-study endpoint and differs slightly from week 12 value; P values vs EZE monotherapy were determined by an analysis of covariance model with terms for treatment and statin intolerance and baseline value as a covariate. EZE, ezetimibe; LS, least square. (13) 18 (18) 19 (19) 5 (19) 10 (42) Discontinuation due to AEs
Urinary tract infection 0 4 (4) 6 (6) 0 1 (4)
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; EZE, ezetimibe. Values are n (%). *Serious AEs included 1 patient with hemothorax and 1 patient with sudden death (ETC-1002,120 mg), pancreatitis relapse (ETC-1002 180 mg), and transient ischemic attack (EZE). †AEs were categorized as drug related if relationship to study drug was deemed possible, probable, or definite, or if relationship to study drug was not recorded. The most common drug-related AEs were muscle spasms (3%), peripheral edema (2%), myalgia (2%), and muscle weakness (2%) with ETC-1002 120 mg; upper respiratory tract infection (2%), abnormal liver function test (2%), and pruritus (2%) with ETC-1002 180 mg; myalgia (6%), arthralgia (4%), and muscle spasms (3%) with EZE; and increased ALT (8%), increased AST (8%), and myalgia (8%) in the ETC-1002 120 mg plus EZE combination group. No drug-related AE was experienced by .1 patient treated with ETC-1002 180 mg plus EZE.
‡Most common AEs were those occurring in $5% patients/group. (14) 6 (12) 9 (18) 2 (17) 2 ( *Prespecified analysis of all musculoskeletal and connective tissue disorders AE terms except arthralgia, back pain, bone pain, bunion, bursitis, groin pain, intervertebral degeneration, intervertebral disc protrusion, joint stiffness, joint swelling, neck pain, osteoarthritis, plantar fasciitis, rotator cuff syndrome, and synovial cyst.
plus EZE. One patient treated with ETC-1002 120 mg plus EZE experienced a CK level .10 times the upper limit of normal, which occurred after heavy physical exertion and was accompanied by myalgia.
Discussion
In this phase 2b study, ETC-1002 alone reduced LDL-C up to 30%, which was significantly greater than the reduction achieved with EZE monotherapy. The greatest mean reductions in LDL-C, which reached 43% and 48%, occurred with the combination of ETC-1002 120 mg or 180 mg with EZE, respectively. The decreases in LDL-C with ETC-1002, EZE, and the combination occurred within 2 weeks of treatment and were maintained throughout the study. LDL-C reductions in statin-intolerant patients appeared similar to those in statin-tolerant patients. This finding is noteworthy considering that statin-intolerant patients had a higher baseline risk for cardiovascular disease than did statin-tolerant patients, with 28% vs 12% classified as ''high'' or ''very high'' risk per NCEP ATP III criteria, respectively. ETC-1002 alone or with EZE also reduced secondary lipid endpoints including non-HDL-C, total cholesterol, apolipoprotein B, and LDL particle number significantly more than EZE alone. CRP decreased more with ETC-1002 alone and ETC-1002 180 mg plus EZE than with EZE alone. There were no significant differences between ETC-1002 and EZE for triglycerides, HDL particle number, and VLDL particle number, but ETC-1002 did reduce HDL-C slightly.
ETC-1002 120 mg and ETC-1002 180 mg were well tolerated both alone and combined with EZE 10 mg daily, and safety profiles were similar across all treatment groups. Frequencies of muscle-related AEs were low in all treatment groups and more common in patients with a history of statin intolerance. The greater LDL-C-lowering effect of ETC-1002 vs EZE did not produce more musclerelated AEs. Rather, rates of muscle-related AEs were slightly lower with ETC-1002 monotherapy than with EZE alone. This is the first clinical study to assess ETC-1002 combined with EZE, the agent most commonly prescribed for patients with statin intolerance. 5 The incremental LDL-C reduction with combination therapy is likely due to the complementary mechanisms of action of the 2 drugs: inhibition of hepatic cholesterol synthesis with ETC-1002 7, 8 and inhibition of intestinal cholesterol absorption with EZE. 13 The 43% to 48% reduction in LDL-C with ETC-1002 120 mg or 180 mg plus EZE is comparable to the 42% to 56% LDL-C reduction observed when EZE is combined with moderate-dose statins 13 and to the $50% reduction with high-intensity statin monotherapy. 6 The results from this study are consistent with findings from earlier studies comparing ETC-1002 with placebo. ETC-1002 in doses up to 120 mg daily reduced LDL-C by 27% in patients with hypercholesterolemia treated for 12 weeks 10 and by 43% in diabetic patients with hypercholesterolemia treated for 4 weeks.
11 ETC-1002 was well tolerated in these trials, with an AE profile similar to placebo. 10, 11 In a trial of 56 hypercholesterolemic patients with a history of statin-associated muscle complaints treated for 8 weeks, ETC-1002 in doses up to 240 mg daily reduced LDL-C by 32% from baseline (P , .0001 compared with placebo). 12 Muscle-related AEs occurred with similar frequency with ETC-1002 and placebo and caused no discontinuations in the ETC-1002-treated patients. 12 Reductions in CRP achieved with ETC-1002 monotherapy in the present study (up to 40%) also were observed in previous studies (41% to 42%). 11, 12 Patients with a history of statin-associated muscle symptoms are difficult to treat. Current recommendations for the management of patients with statin-associated muscle symptoms include the use of maximally tolerated statins combined with nonstatin lipid-lowering therapies as needed. 4, 14 EZE has been shown to reduce LDL-C by 16% to 17% in statin-intolerant patients 15, 16 and is recommended for statin-intolerant patients, as are bile acid sequestrants, which may be poorly tolerated and fenofibrate. 4, 14 Colesevelam 17 and fenofibrate 18 can reduce LDL-C by approximately 20% in hypercholesterolemic patients but have not to our knowledge been studied in patients with statin-associated muscle symptoms. The investigational proprotein convertase subtilisin/kexin type 9 inhibitors may offer a future therapeutic alternative for patients with statin-associated muscle complaints. 4 Evolocumab lowered LDL-C up to 56% after 12 weeks of treatment in statin-intolerant patients, 19 and alirocumab lowered LDL-C by 45% after 24 weeks of treatment in statin-intolerant patients. 20 There are limitations to the present study. The overall sample size was relatively small, and the combination treatment group was 25% the size of the monotherapy groups. This design was used because the primary goal was to compare LDL-C effects between ETC-1002 (120 mg or 180 mg) and EZE monotherapy. The study did not include a placebo group but used EZE as an active comparator because it is commonly prescribed to statin-intolerant patients. Baseline triglyceride and CRP levels differed among the treatment groups, and the effect of these differences is unknown. Some study participants were statin tolerant, but this diagnosis was not tested with a statin-treatment arm.
Conclusion
There is a need for alternative oral treatment strategies for hypercholesterolemic patients who cannot sufficiently reduce their LDL-C with available agents, including patients with intolerance to statins. 1, 21 The results of this study suggest that ETC-1002 with or without EZE may be a useful treatment in patients with hypercholesterolemia, including those who are unable to tolerate statins because of muscle side effects.
